Spots Global Cancer Trial Database for Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome
Official Title: Open Label, Dose Escalation, Followed by Open Label,Single Arm Clinical Trial of HuMax-CD4 in Patients With Mycosis Fungoides Type CTCL (Stage IB-IVB) or Sezary Syndrome Who Are Refractory or Intolerant to Targretin® (Bexarotene) and One Other Standard Therapy
Study ID: NCT00127881
Interventions
Study Description
Brief Summary: The purpose of this study is to determine the efficacy of the drug, HuMax-CD4, in patients with mycosis fungoides(MF) and sezary syndrome who are intolerant to or do not respond to treatment with Targretin® and one other standard therapy.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States
Stanford University Medical Center, Stanford, California, United States
University of Colorado, Aurora, Colorado, United States
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
The Emory Clinic, Atlanta, Georgia, United States
Northwestern University, Chicago, Illinois, United States
Tulane University Health Science Center, New Orleans, Louisiana, United States
Boston Medical Center, Boston, Massachusetts, United States
University of Michigan Medical Center, Ann Arbor, Michigan, United States
Memorial Sloan Kettering, New York City, New York, United States
New York Medical Center, New York, New York, United States
SUNY Upstate Medical University, Syracuse, New York, United States
Duke University Medical Center, Durham, North Carolina, United States
University Hospital of Cleveland, Cleveland, Ohio, United States
Ohio State University, Columbus, Ohio, United States
Oregon Health & Science University, Portland, Oregon, United States
University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
Middle Tennessee Research Institute, Nashville, Tennessee, United States
MD Anderson Cancer Center, Houston, Texas, United States
Hopital de I'Hotel-Dieu, Lyon Cedex 02, , France
Consultation Dermatologie Niveau moins 1 Hopital Archet 2, Nice, , France
Hopital Saint-Louis Service de Dermatologie, Paris Cedex 10, , France
Centre Hospitalier Lyon Sud Bat. 1F 1er etage service Hematologie, Pierre Benite Cedex, , France
Skin Cancer Center Charite Mitte Dermatologie Fran Ramona Kursawa, Berlin, , Germany
University of Essen - Universitatsklinikum Essen z. Hd. Frau Desire Zieling, Essen, , Germany
University of kiel, Klinik Fur Dermotologie, Christian-Albrechts-Universitat Zu, Kiel, , Germany
Klinikum Minden / Hautklinik Minden, Minden, , Germany
University of Wurzburg - Universitatsklinikum Wurzburg dermato-onkologische studien, Wurzburg, , Germany
Instituto di Ematologia e Oncologia Medica "L. & A. Seragnoli", Bologna, , Italy
Day Hospital Oncologico-Presidio Ospedaliero Firenze Centro Ospedale Santa Maria Nuova Azienda Sanitaria di Firenze, University of Florence, Florence, , Italy
University of Milan-Fondazione IRCCS di Natura Pubblica Ospedale Maggiore Policlinico Mangiagalli e Regina Elena di Milano via Francesco Sforza, Milan, , Italy
Instituto Dermopatico dell'Immacolata IRCCS via Monti di Creta, Roma, , Italy
University of Turin SCDU Dermosifilopatia 2 A.S.O. Molinette S.Giovanni Battista, Turin, , Italy
Hospital Universitario de la Princesa, Madrid, , Spain
Maternidad Planta Baja, Hospital 12 de Octubre, Madrid, , Spain
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
